One study that investigated the outcomes of both mucosal and acral melanoma treatment with PDL-1 inhibitors showed an 11.5% response rate to treatment.[9] D’angelo et al examined the efficacy and safety of nivolumab alone and in combination with ipilimumab in patients with mucosal melanoma. This evidence concerns the gene CD274 and acral lentiginous melanoma.